Davood Goodarzi, Ali Cyrus, Mohamood Reza Baghi-Nia, Esmaeil Azimi Shahrabi, Mastafa Delavar, Fereshteh Arian-Far,
Volume 9, Issue 4 (12-2006)
Abstract
Introduction: Benign Prostatic Hyperplasia (BPH) is the most common benign tumor in men. Due to the side effects of chemical drugs, phytotherapy has become a treatment method in BPH since 1990s. Prostatan is a plant extract widely available in Iran. In this study, we evaluated the therapeutic effects of Prostatan drop in combination with Prazosin in alleviating BPH symptoms. Materials and Methods: In a single blind randomized clinical trial , 66 men over 50 years with BPH symptoms who were visited in Vali-e-Asr hospital of Arak were randomly divided in two groups and treated with either Prostatan (40 drop,TDS) plus Prazosin (1mg, BD)or Prazosin (1mg, BD)alone . AUA symptom score, PSA (prostate-specific antigen) levels, Prostate volume, post voidal residue (PVR) by sonograms and uroflowmetry results were determined before and 12 weeks after treatment. Data was analyzed by T and Man- Whithey u tests. Results: Before treatment there were no significant differences in age, PSA, PVR, AUA symptom score, Prostate volume and uroflowmetry between the two groups. After treatment the mean of PSA levels, Prostate volume and PVR did not differ between the two groups. In the Prostatan plus Prazosin group, the mean of AUA symptom score was 3.3 less (p<0.0001) and the mean of maximal urine flow rate was 2.7 ml/s more than the Prazosin group (p<0.0001). Conclusion: Regarding results, it seems that adding Prostatan to Prazosin against Prazosin alone enhances its effects on controlling BPH symptoms and increases urine flow rates.
Mahmood Reza Baghinia, Seyyed Mehdi Shariatzadeh, Neda Baghinia,
Volume 16, Issue 10 (1-2014)
Abstract
Background: Prostate cancer is one of the most prevalent type of cancer and the second cause of death among American men. Its prevalence has a direct relationship with increasing age. The present study was carried out to determine the level of prostate specific antigen (PSA) and calcium level in blood in men with prostate cancer and BPH in Arak.
Materials and Methods: In this prospective study, out of 400 Arak males, were selected from different inner-city areas through cluster sampling during a period of two years (august 2011-august 2012). After the population was approved to have the necessary criteria to be included in the study, their PSA and calcium level was measured and its mean in over 40 years. In order to determine mean difference among the seven groups T-test analysis and to determine "PSA", PSA Assay and Tandem-R kits were utilized and for measurement of serum calcium, pars azmoon kit was used.
Results: In this study, there was a markedly relationship between age and serum calcium and serum PSA in both groups.in this way that there was a negative relationship between age and serum calcium and a positive relationship between age and serum PSA.
Conclusion: With respect to the findings of the study, it could be confirmed that was a markedly relationship between serum PSA and serum calcium only in prostatic cancer patients,according to this study in future maybe we used serum calcium as a tumor-marker for screening for prostate cancer.
